{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Partial Response (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Treatment response and evaluation will be performed using standardized lymphoma International Working Group recommendations.\\>\n\n\\> A Complete Response (CR) requires:\\>\n\n* Complete disappearance of all detectable clinical and radiographic evidence of\\> disease.\\>\n* All lymph nodes and nodal masses must have regressed to normal size.\\>\n\nPartial Response (PR):\\>\n\n* greater than 50% decrease in Sum of Product Dimensions of the six largest dominant nodes, nodal masses, or skin lesions.\\>\n* No increase in size of other nodes\\>\n* no new sites of disease.","groups":[{"description":"Starting Dose Level 1= 0.15 mg/kg\\> Each cycle is 4 weeks.\\> \\> Cycle 1 and 2:\\> Alefacept by IV Weekly\\>\n\n\\> Cycles 3-12:\\> Alefacept by IV 1 x every 4 weeks","id":"OG000","title":"Dose Level 1"},{"description":"Dose Level 2= 0.20 mg/kg\\> Each cycle is 4 weeks.\\> \\> Cycle 1 and 2:\\> Alefacept by IV Weekly\\>\n\n\\> Cycles 3-12:\\> Alefacept by IV 1 x every 4 weeks","id":"OG001","title":"Dose Level 2"},{"description":"Dose Level 3= 0.30 mg/kg\\> Each cycle is 4 weeks.\\> \\> Cycle 1 and 2:\\> Alefacept by IV Weekly\\>\n\n\\> Cycles 3-12:\\> Alefacept by IV 1 x every 4 weeks","id":"OG002","title":"Dose Level 3"}],"paramType":"NUMBER","populationDescription":"Two patients from Dose level 2 were not able to complete cycle 1 and were not evaluated for dose limiting toxicity.","reportingStatus":"POSTED","timeFrame":"up to 12 cycles (28 days per cycle) of treatment.","title":"Clinical Response","type":"SECONDARY","unitOfMeasure":"participants"}